Globally, about 100,000 children have lost their lives to measles and rubella.

Indian Immunological Ltd. (IIL) is a major supplier to India’s UIP.

IIL has introduced Mebella™, also named Mabella, a lyophilized, live attenuated vaccine for measles and rubella (MR).

It has been developed in partnership with the Polyvac Institute in Vietnam.

Extensive human clinical trials have affirmed its safety and efficacy.

A Phase II/III clinical trial showed Mebella™ to have seroprotection and seroconversion rates, assessed at 42 days, at par with and non-inferior to the MR-VAC® vaccine.